Lv5
1050 积分 2023-05-09 加入
Savolitinib: First Approval
2个月前
已完结
<p>Response and acquired resistance to savolitinib in a patient with pulmonary sarcomatoid carcinoma harboring <em>MET</em> exon 14 skipping mutation: a case report</p>
2个月前
已完结
Savolitinib: A Promising Targeting Agent for Cancer
2个月前
已完结
Bortezomib plus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 Trial
2个月前
已完结
Savolitinib: First Approval
2个月前
已完结
MET-Targeted Therapies and Clinical Outcomes: A Systematic Literature Review
2个月前
已完结
INSIGHT 2: a phase II study of tepotinib plus osimertinib in MET-amplified NSCLC and first-line osimertinib resistance
2个月前
已完结
MET As a Possible Target for Non–Small-Cell Lung Cancer
2个月前
已关闭
1379P Preliminary results of phase II KUNPENG study of vebreltinib in patients (Pts) with advanced NSCLC harboring c-MET alterations
2个月前
已完结
皖公网安备34019202002308
